Who
Kurt Graves
Director
Company insider
Files Form 4 as: Director, Seres Therapeutics; Director, Radius Health; Director, Achillion Pharmaceuticals; Director, Pulmatrix; EVP, Chief Commercial Officer, Vertex Pharmaceuticals.
In numbers
- Trades disclosed
- 106
- Buys
- 1
- Sells
- 16
- Bought
- $100K
- Sold
- $5.6M
- Companies
- 5
- Companies where not an officer
- 4
- First trade
- 17 Jul 2007
- Last trade
- 8 Jul 2026
- Last filed
- 10 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 Jul 2026filed 10 Jul 2026 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,500 at $0.00 | filing |
| 8 Jul 2026filed 10 Jul 2026 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,500 at $0.00 | filing |
| 10 Apr 2025filed 11 Apr 2025 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 1 Jul 2024filed 3 Jul 2024 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —64,564 at $0.00 | filing |
| 4 Apr 2024filed 8 Apr 2024 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 22 Jun 2023filed 23 Jun 2023 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 22 Jun 2022filed 24 Jun 2022 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 22 Jun 2022filed 24 Jun 2022 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 16 Jun 2021filed 21 Jun 2021 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,000 at $0.00 | filing |
| 18 Jun 2020filed 22 Jun 2020 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 20 Feb 2020filed 24 Feb 2020 | Radius Healthoption or derivative | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 20 Feb 2020filed 24 Feb 2020 | Radius Health | SEC FORM 4 Code A | —5,500 | filing |
| 28 Jan 2020filed 29 Jan 2020 | Achillion Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —30,000 | filing |
| 28 Jan 2020filed 29 Jan 2020 | Achillion Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —135,000 | filing |
| 28 Jan 2020filed 29 Jan 2020 | Achillion Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —30,000 | filing |
| 28 Jan 2020filed 29 Jan 2020 | Achillion Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —25,000 | filing |
| 28 Jan 2020filed 29 Jan 2020 | Achillion Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —30,000 | filing |
| 28 Jan 2020filed 29 Jan 2020 | Achillion Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —42,000 | filing |
| 28 Jan 2020filed 29 Jan 2020 | Achillion Pharmaceuticals | SEC FORM 4 Code D | $143K22,709 at $6.30 | filing |
| 13 Jun 2019filed 14 Jun 2019 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
News
Head to Head Analysis: Caribou Biosciences (NASDAQ:CRBU) & Vertex Pharmaceuticals (NASDAQ:VRTX)VRTX · tickerreport.com · 14 Oct 2026Vertex Pharmaceuticals Incorporated: Vertex to Present New Data on ALYFTREK at the North American Cystic Fibrosis ConferenceVRTX · finanznachrichten.de · 9 Oct 2026
0 headlines in the last 90 days name Kurt Graves; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.